Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2026. The document serves as a transaction notification regarding a specific insider trade rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a single transaction involving American Depositary Shares (ADS).
| Metric | Value |
|---|---|
| Transaction Price | $49.6700 |
| Transaction Volume | 74 ADS |
| Transaction Date | May 15, 2026 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an acquisition of 74 ADS by Dr. Hal Barron, a Non-Executive Director, within his GSK 401(k) plan account following the reinvestment of dividends.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains only a standard corporate description stating GSK is a global biopharma company.
Investor Verification Checklist
- Verify the total holdings of Dr. Hal Barron post-transaction to assess insider ownership levels.
- Confirm the market price of GSK ADS on May 15, 2026, to validate the reported transaction price of $49.67.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as this filing does not contain them.